PhotonPharma
Business Services · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3185 Rampart Rd Ste D230, Fort Collins, ...Revenue
<$5 MillionIndustry
About PhotonPharma
PhotonPharma Inc. specializes in developing innovative therapies for solid tumor cancers, with a focus on their product Innocell, an autologous vaccine designed to delay disease progression in patients. The company is currently conducting a Phase 1 clinical study to assess the safety and immunogenicity of Innocell in patients with recurrent epithelial ovarian cancer. Their intended clients are patients aged 18 and older who are facing challenges with this specific type of cancer. PhotonPharma aims to enhance treatment outcomes in conjunction with existing therapies such as chemotherapy, immunotherapy, and surgery.Explore more
PhotonPharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to PhotonPharma
Compare insights from companies similar to PhotonPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PhotonPharma Tech Stack
A closer look at the technologies used by PhotonPharma
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PhotonPharma
Sign Up For FreeTo access detailed company insights
PhotonPharma Inc. specializes in developing innovative therapies for solid tumor cancers, with a focus on their product Innocell, an autologous vaccine designed to delay disease progression in patients. The company is currently conducting a Phase 1 clinical study to assess the safety and immunogenicity of Innocell in patients with recurrent epithel... Read More
